Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apalutamide + docetaxel
- Development stage
- Unknown
- Lead developer
- Qilu Hospital of Shandong University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apalutamide + docetaxel is a combination therapy investigated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), typically administered in conjunction with androgen deprivation therapy (ADT) as a triplet regimen. Apalutamide is a second-generation selective androgen receptor (AR) antagonist that works by binding directly to the ligand-binding domain of the AR, thereby inhibiting its nuclear translocation, DNA binding, and transcription of androgen-responsive genes. Docetaxel is a cytotoxic taxane that promotes the assembly of tubulin into stable microtubules and inhibits their disassembly, leading to cell cycle arrest in the G2/M phase and subsequent apoptosis. This combination is particularly studied in patients with high-volume or high-burden metastatic disease to improve clinical outcomes such as progression-free survival and overall survival compared to standard doublet therapies.
- Brand names
- ErleadaTaxotere
- Other names
- apantamide + docetaxelapalutamide + docetaxel + ADTapantamide + docetaxel + ADT
02
Targets
TUBB (Tubulin (alpha and beta subunits))AR (Adrenergic receptors)
Beyond the preview
Go deeper on apalutamide + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apalutamide + docetaxel.